Indication
Recurrent B-Cell Prolymphocytic Leukemia
1 clinical trial
1 product
2 drugs
Clinical trial
Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)Status: Recruiting, Estimated PCD: 2025-04-30
Drug
cyclophosphamideDrug
fludarabine